Phaseline

Targets › RIBOSOME

RIBOSOME: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Mar 2028.

Open in Phaseline: the race on RIBOSOME, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
David BoulwareLinezolid
Bacterial 70S ribosome inhibitor
RIBOSOMEPhase 2Tuberculous MeningitisMar 2028

Conditions

Tuberculous Meningitis (1)

Modalities

small molecule (1)

Companies

David Boulware (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.